Innoviva Acquires La Jolla Pharmaceutical Company
July 11, 2022
Innoviva entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company for $6.23 per share in cash (including a tender offer), representing an implied enterprise value of about $149 million. The acquisition adds GIAPREZA and XERAVA to Innoviva’s infectious disease and hospital portfolio and was completed in August 2022, with La Jolla becoming a wholly owned subsidiary and delisted from Nasdaq.
- Buyers
- Innoviva, Inc., Innoviva (wholly owned subsidiary)
- Targets
- La Jolla Pharmaceutical Company
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.